![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 30, 2023
Reflections on the spring conference season, including highlights from the recent Group Meeting; updates on the ComboMATCH precision medicine initiative
June 30, 2023
Earlier this year, Puerto Rico lost its preeminent champion for cancer research
June 30, 2023
This phase 2 trial is testing how well FDG-PET/CT imaging can predict response to standard-of-care neoadjuvant therapy in patients with HER2-positive breast cancer
June 30, 2023
This phase 2 trial is evaluating the activity of nilotinib-paclitaxel in patients with solid tumors and exploring predictive biomarkers of response and resistance
June 30, 2023
The Group is recognizing Dr. Forde as an exceptional physician-scientist who is making significant research contributions as a translational thoracic cancer investigator
June 30, 2023
The Group is recognizing Dr. Forastiere for her sustained commitment to developing women’s careers in cancer medicine and advancing women investigators in ECOG-ACRIN
June 30, 2023
At a recent meeting, ECOG-ACRIN leaders and members celebrated the conclusion of enrollment to the landmark NCI-MATCH clinical trial
June 30, 2023
This phase 3 study aims to determine the optimal sequencing of surgery, chemotherapy, and chemoradiotherapy for patients with cancer of the penis
June 30, 2023
Researchers presented numerous research abstracts and trial updates at the 2023 ASCO Annual Meeting
June 30, 2023
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 19, 2023
The ComboMATCH registration trial opens; NCI creates Clinical Trials Innovation unit, unveils revised National Cancer Plan
April 19, 2023
ComboMATCH researchers are discovering new drug combinations that show promise for patients with advanced cancers, based on strong pre-clinical in vivo evidence of therapeutic effectiveness